ML385 (Standard)
ML385 (Standard) is the analytical standard of ML385 (HY-100523). This product is intended for research and analytical applications. ML385 is a potent and selective Nrf2 inhibitor with an IC50 of 1.9 μM. ML385 directly binds to the Neh1 domain of NRF2, interferes with the binding of the MAFG-NRF2 protein complex to the antioxidant response element (ARE) DNA sequence, thereby blocking the expression of downstream target genes of NRF2. ML385 can be used in studies related to adult T-cell leukemia, breast cancer, myocardial ischemia/reperfusion injury, non-small cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and lung squamous cell carcinoma.
For research use only. We do not sell to patients.
- Purity : 98%
- CAS No.: 846557-71-9
- Formula: C29H25N3O4S
- Molecular Weight:511.59
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 846557-71-9
-
Molecular Weight 511.59
-
Formula C29H25N3O4S
-
SMILES
O=C(NC1=NC(C2=CC=C(N(C(C3=C(C)C=CC=C3)=O)CC4)C4=C2)=C(C)S1)CC5=CC(OCO6)=C6C=C5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- ML385 (Standard)
- 846557-71-9
- Reference Standards
- Keap1-Nrf2
- Ferroptosis
- Apoptosis
- mTOR
- Mammalian target of Rapamycin
- Nrf2
- head and neck squamous cell carcinoma
- PBMCs
- Neh1 domain
- tamoxifen-resistant breast cancer
- lung squamous cell carcinoma
- esophageal squamous cell carcinoma
- Jurkat T cells
- non-small cell lung cancer
- adult T-cell leukemia
- Inhibitor
- inhibitor
- inhibit